Phillip Bennett, MD, PhD

Obstetrician and Gynaecologist, Director, Institute for Reproductive and Developmental Biology, Imperial College, London – Professor of Obstetrics and Gynaecology, Imperial College, London.

Phillip Bennett was born and educated in Kent (U.K.) and did undergraduate medical education at St George’s Hospital London, qualifying in 1982.  He then pursued a split career, spending half his time in basic science research and half in clinical postgraduate training.

He became Doctor of Medicine by research and a member of the Royal College of Obstetricians and Gynaecologists in 1988, obtained a PhD in Molecular Biology in 1993 and was elected Fellow of the RCOG in 2000. He has been Professor of Obstetrics and Gynaecology in Imperial College Faculty of Medicine since 1996. Professor Bennett became Director of the Institute of Reproductive and Developmental Biology, Imperial College London in June 2012.

His research interests are in the basic science and clinical aspects of preterm birth.

Leave a Reply

Your email address will not be published. Required fields are marked *

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue